FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311774306> ?p ?o ?g. }

• W4311774306 endingPage "e2246928" @default.
• W4311774306 startingPage "e2246928" @default.
• W4311774306 abstract "Increasing numbers of post hoc analyses have applied restricted mean survival time (RMST) analysis on the aggregated-level data from clinical trials to report treatment effects, but studies that use individual-level claims data are needed to determine the feasibility of RMST analysis for quantifying treatment effects among patients with type 2 diabetes in routine clinical settings.To apply RMST analysis for assessing sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated cardiovascular (CV) events and estimating heterogenous treatment effects (HTEs) on CV and kidney outcomes in routine clinical settings.This comparative effectiveness study of Taiwan's National Health Insurance Research Database examined 21 144 propensity score (PS)-matched pairs of patients with type 2 diabetes with SGLT2i and dipeptidyl peptidase-4 inhibitor (DPP4i) treatment for assessing CV outcomes, and 19 951 PS-matched pairs of patients with type 2 diabetes with SGLT2i and DPP4i treatment for assessing kidney outcomes. Patients were followed until December 31, 2018. Statistical analysis was performed from August 2021 to April 2022.Newly stable SGLT2i or DPP4i use in 2017.Study outcomes were CV events including hospitalization for heart failure (HHF), 3-point major adverse CV events (3P-MACE: nonfatal myocardial infarction [MI], nonfatal stroke, and CV death), 4-point MACE (4P-MACE: HHF and 3P-MACE), and all-cause death, and chronic kidney disease (CKD). RMST and Cox modeling analyses were applied to estimate treatment effects on study outcomes.After PS matching, the baseline patient characteristics were comparable between 21 144 patients with stable SGLT2i use (eg, mean [SD] age: 58.3 [10.7] years; 11 990 [56.7%] male) and 21 144 patients with stable DPP4i use (eg, mean [SD] age: 58.1 [11.6] years; 12 163 [57.5%] male) for assessing CV outcomes, and those were also comparable between 19 951 patients with stable SGLT2i use (eg, mean [SD] age: 58.1 [10.7] years; 11 231 [56.2%] male) and 19 951 patients with stable DPP4i use (eg, mean [SD] age: 57.9 [11.5] years; 11 340 [56.8%] male) for assessing kidney outcome. The 2-year difference in RMST between patients with SGLT2i use and patients with DPP4i use was 4.99 (95% CI, 3.56-6.42) days for HHF, 4.12 (95% CI, 2.72-5.52) days for 3P-MACE, 7.72 (95% CI, 5.83-9.61) days for 4P-MACE, 1.26 (95% CI, 0.47-2.04) days for MI, 2.70 (95% CI, 1.57-3.82) days for stroke, 0.69 (95% CI, 0.28-1.11) days for CV death, 6.05 (95% CI, 4.89-7.20) days for all-cause death, and 14.75 (95% CI, 12.99-16.52) days for CKD. Directions of hazard ratios from Cox modeling analyses were consistent with RMST estimates. No association was found between study treatment and the negative control outcome (dental visits for tooth care). Consistent results across sensitivity analyses using high-dimensional PS-matched and PS-weighting approaches supported the validity of primary analysis results. Largest difference in RMST of SGLT2i vs DPP4i use for HHF and CKD was found among patients with established heart failure (30.80 [95% CI, 5.08-56.51] days) and retinopathy (40.43 [95% CI, 31.74-49.13] days), respectively.In this comparative effectiveness study, RMST analysis was feasible for translating treatment effects into more clinical intuitive estimates and valuable for quantifying HTEs among diverse patients in routine clinical settings." @default.
• W4311774306 created "2022-12-28" @default.
• W4311774306 creator A5000139592 @default.
• W4311774306 creator A5010510895 @default.
• W4311774306 creator A5013577973 @default.
• W4311774306 creator A5046300417 @default.
• W4311774306 creator A5064013873 @default.
• W4311774306 creator A5070191522 @default.
• W4311774306 date "2022-12-15" @default.
• W4311774306 modified "2023-10-14" @default.
• W4311774306 title "Restricted Mean Survival Time Analysis to Estimate SGLT2i–Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan" @default.
• W4311774306 cites W1849521086 @default.
• W4311774306 cites W1967862917 @default.
• W4311774306 cites W1981535076 @default.
• W4311774306 cites W1982967337 @default.
• W4311774306 cites W1984732538 @default.
• W4311774306 cites W2009428399 @default.
• W4311774306 cites W2011284201 @default.
• W4311774306 cites W2072013249 @default.
• W4311774306 cites W2088000704 @default.
• W4311774306 cites W2242199646 @default.
• W4311774306 cites W2275034928 @default.
• W4311774306 cites W2284187917 @default.
• W4311774306 cites W2293193799 @default.
• W4311774306 cites W2507759746 @default.
• W4311774306 cites W2565763095 @default.
• W4311774306 cites W2753244592 @default.
• W4311774306 cites W2760699482 @default.
• W4311774306 cites W2790363119 @default.
• W4311774306 cites W2902410605 @default.
• W4311774306 cites W2924473453 @default.
• W4311774306 cites W2937710358 @default.
• W4311774306 cites W2943005888 @default.
• W4311774306 cites W2966231525 @default.
• W4311774306 cites W2982188023 @default.
• W4311774306 cites W3012581184 @default.
• W4311774306 cites W3084246714 @default.
• W4311774306 cites W3092566692 @default.
• W4311774306 cites W3130705965 @default.
• W4311774306 cites W3150612515 @default.
• W4311774306 cites W3156709753 @default.
• W4311774306 cites W3168955582 @default.
• W4311774306 cites W3180841526 @default.
• W4311774306 cites W3201140601 @default.
• W4311774306 cites W4200439235 @default.
• W4311774306 cites W4220699005 @default.
• W4311774306 cites W4221064928 @default.
• W4311774306 cites W4235932872 @default.
• W4311774306 cites W4243402014 @default.
• W4311774306 cites W4253116150 @default.
• W4311774306 cites W4254637496 @default.
• W4311774306 doi "https://doi.org/10.1001/jamanetworkopen.2022.46928" @default.
• W4311774306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36520437" @default.
• W4311774306 hasPublicationYear "2022" @default.
• W4311774306 type Work @default.
• W4311774306 citedByCount "6" @default.
• W4311774306 countsByYear W43117743062023 @default.
• W4311774306 crossrefType "journal-article" @default.
• W4311774306 hasAuthorship W4311774306A5000139592 @default.
• W4311774306 hasAuthorship W4311774306A5010510895 @default.
• W4311774306 hasAuthorship W4311774306A5013577973 @default.
• W4311774306 hasAuthorship W4311774306A5046300417 @default.
• W4311774306 hasAuthorship W4311774306A5064013873 @default.
• W4311774306 hasAuthorship W4311774306A5070191522 @default.
• W4311774306 hasBestOaLocation W43117743061 @default.
• W4311774306 hasConcept C126322002 @default.
• W4311774306 hasConcept C134018914 @default.
• W4311774306 hasConcept C17923572 @default.
• W4311774306 hasConcept C203092338 @default.
• W4311774306 hasConcept C207103383 @default.
• W4311774306 hasConcept C2777180221 @default.
• W4311774306 hasConcept C2777451236 @default.
• W4311774306 hasConcept C2780400711 @default.
• W4311774306 hasConcept C2780739214 @default.
• W4311774306 hasConcept C44249647 @default.
• W4311774306 hasConcept C500558357 @default.
• W4311774306 hasConcept C50382708 @default.
• W4311774306 hasConcept C535046627 @default.
• W4311774306 hasConcept C555293320 @default.
• W4311774306 hasConcept C71924100 @default.
• W4311774306 hasConceptScore W4311774306C126322002 @default.
• W4311774306 hasConceptScore W4311774306C134018914 @default.
• W4311774306 hasConceptScore W4311774306C17923572 @default.
• W4311774306 hasConceptScore W4311774306C203092338 @default.
• W4311774306 hasConceptScore W4311774306C207103383 @default.
• W4311774306 hasConceptScore W4311774306C2777180221 @default.
• W4311774306 hasConceptScore W4311774306C2777451236 @default.
• W4311774306 hasConceptScore W4311774306C2780400711 @default.
• W4311774306 hasConceptScore W4311774306C2780739214 @default.
• W4311774306 hasConceptScore W4311774306C44249647 @default.
• W4311774306 hasConceptScore W4311774306C500558357 @default.
• W4311774306 hasConceptScore W4311774306C50382708 @default.
• W4311774306 hasConceptScore W4311774306C535046627 @default.
• W4311774306 hasConceptScore W4311774306C555293320 @default.
• W4311774306 hasConceptScore W4311774306C71924100 @default.
• W4311774306 hasIssue "12" @default.
• W4311774306 hasLocation W43117743061 @default.
• W4311774306 hasLocation W43117743062 @default.

• next